RE:RE:RE:RE:National Cancer Institute Clinical Trial Planning NMIBCI think pdc technology may have been written off because in previous attempts there was no way to ensure the cancer cells received more of the pdc than the surrounding healthy tissue. So when light activated both cancer cells and healthy cells suffered damage. Theralase has solved this problem with it's new class of pdcs which are preferentially taken up by cancer cells. The fact that pdc technology now has the prospect of being extremely effective without side effects seems to have gone unnoticed. Human trials will provide the proof.
vestor111 wrote: Indeed I also noticed no reference to PDC's which made me wonder if they had possibly be written off in favor of more sexy therapies du jour like immuno cocktails. If PDC are passe, this could explain the lack of attention to what TLT is bring to the table.